Company / R&D Expense
Protagonist Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$159.3M
FY2025
5-year range
$120.2M / $159.3M
FY2021-FY2025
Trend
+15.3%
vs FY2024
Sector context
#102 of 210
Health Care
What the data says
At $159M, Protagonist Therapeutics, Inc.'s r&d expense ranks #102 of 210 in the Health Care sector. Improved from $120M to $159M over the past 2 years.
Based on SEC 10-K filings.
$159M in FY2025 with a 5-year CAGR of +16.4%.
Improved from $120M to $159M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +8.1%
- 5-Year CAGR
- +16.4%
- 10-Year CAGR
- -
Sector benchmark
#102 of 210 in Health CareTop 49% of 210This company $159.3M Sector average $644.1M
▼
-75.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.4%, indicating consistent growth.
- In FY2025, r&d expense increased 15.3% year-over-year.
- Ranks #102 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $159.3M | +15.3% |
| FY2024 | $138.1M | +15.0% |
| FY2023 | $120.2M | -4.8% |
| FY2022 | $126.2M | +0.2% |
| FY2021 | $126.0M | +69.1% |
| FY2020 | $74.5M | +14.6% |
| FY2019 | $65.0M | +9.3% |
| FY2018 | $59.5M | +28.8% |
| FY2017 | $46.2M | +79.7% |
| FY2016 | $25.7M | +117.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026